Volume: 5, 2026
5th International PhD Students’ Conference at the University of Life Sciences in Lublin, Poland:
ENVIRONMENT – PLANT – ANIMAL – PRODUCT
Abstract number: H003
DOI: https://doi.org/10.24326/ICDSUPL5.H003
Published online: 22 April 2026
CIP2A as predictor of treatment response in plasma cell myeloma
Alicja Bogdanowicz-Żeleźniak*1,2, Aneta Szudy-Szczyrek3, Maciej Korpysz4, Anna Kokoć3, Adrian Juda3, Marek Hus3 and Radosław Mlak1
1 Department of Laboratory Diagnostics, Medical University of Lublin, 1 Chodźki St., 20-093 Lublin, Poland
2 Doctoral School, Medical University of Lublin, 7 Chodźki St., 20-093 Lublin, Poland
3 Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, 2 Karmelicka St., 20-400 Lublin, Poland
4 Department of Biochemical Diagnostics, Medical University of Lublin, 8 Solidarnosci Ave., 20-841 Lublin, Poland
* Corresponding author: alicjabogdanowicz00@gmail.com
Plasma cell myeloma (PCM) is a malignant plasma cell disorder characterised by clonal proliferation within the bone marrow and heterogeneous clinical outcomes. Despite advances in treatment, the disease remains incurable, highlighting the need for reliable predictive biomarkers. Cellular Inhibitor of Protein Phosphatase 2A (CIP2A) is an oncoprotein that inhibits protein phosphatase 2A (PP2A) and contributes to oncogenic signalling. The aim of this study was to evaluate CIP2A gene expression as a predictive factor of treatment response in PCM patients treated with bortezomib-based regimens. The study included 40 patients diagnosed between 2014 and 2024. The cohort was predominantly female (67.5%), with a median age of 65.5 years (range: 37-79), and most patients were classified as stage III according to the International Staging System (35%) and Durie-Salmon classification (85%). Gene expression was assessed using Real-Time polymerase chain reaction (Real-Time PCR). Predictive value was analysed using receiver operating characteristic (ROC) curves. CIP2A expression showed high diagnostic performance for prediction of treatment response after early chemotherapy cycles, with 77.78% sensitivity and 100% specificity after 2 cycles (AUC=0.910; p<0.0001) and 90.91% sensitivity and 100% specificity after 4 cycles (AUC=0.955; p<0.0001). No significant predictive value was observed after 6 and 8 cycles. CIP2A may represent a promising predictive biomarker in PCM; however, further validation is required.
Keywords: bortezomib; CIP2A; plasma cell myeloma; predictive biomarker
How to cite
Bogdanowicz-Żeleźniak A., Szudy-Szczyrek A., Korpysz M., Kokoć A., Juda A., Hus M., Mlak R., 2026. CIP2A as predictor of treatment response in plasma cell myeloma. In: 5th International PhD Students’ Conference at the University of Life Sciences in Lublin, Poland: Environment – Plant – Animal – Product. https://doi.org/10.24326/ICDSUPL5.H003